
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="FF2082FE89B753831A82FE00128AB662.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cureus">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cureus">
<meta name="citation_title" content="Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications">
<meta name="citation_author" content="FNU Arty">
<meta name="citation_author_institution" content="Internal Medicine, Monmouth Medical Center, Long Branch, USA">
<meta name="citation_author" content="Devarashetty Shreya">
<meta name="citation_author_institution" content="Internal Medicine, Monmouth Medical Center, Long Branch, USA">
<meta name="citation_author" content="Aleeza Chaudhry">
<meta name="citation_author_institution" content="Internal Medicine, Monmouth Medical Center, Long Branch, USA">
<meta name="citation_author" content="Sarkar Sohini">
<meta name="citation_author_institution" content="Internal Medicine, Monmouth Medical Center, Long Branch, USA">
<meta name="citation_publication_date" content="2025 Jul 9">
<meta name="citation_volume" content="17">
<meta name="citation_issue" content="7">
<meta name="citation_firstpage" content="e87605">
<meta name="citation_doi" content="10.7759/cureus.87605">
<meta name="citation_pmid" content="40786355">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/pdf/cureus-0017-00000087605.pdf">
<meta name="description" content="Heart failure with preserved ejection fraction (HFpEF) poses a growing public health challenge, characterized by limited therapeutic options and a high burden of comorbid obesity and type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide-1 ...">
<meta name="og:title" content="Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Heart failure with preserved ejection fraction (HFpEF) poses a growing public health challenge, characterized by limited therapeutic options and a high burden of comorbid obesity and type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide-1 ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12333672">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.7759/cureus.87605"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/cureus-0017-00000087605.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333672%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12333672/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12333672/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cureus.png" alt="Cureus logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cureus" title="Link to Cureus" shape="default" href="http://www.cureus.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cureus</button></div>. 2025 Jul 9;17(7):e87605. doi: <a href="https://doi.org/10.7759/cureus.87605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.7759/cureus.87605</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cureus%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cureus%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arty%20FNU%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">FNU Arty</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">FNU Arty</span></h3>
<div class="p">
<sup>1</sup>
Internal Medicine, Monmouth Medical Center, Long Branch, USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arty%20FNU%22%5BAuthor%5D" class="usa-link"><span class="name western">FNU Arty</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shreya%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Devarashetty Shreya</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Devarashetty Shreya</span></h3>
<div class="p">
<sup>1</sup>
Internal Medicine, Monmouth Medical Center, Long Branch, USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shreya%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Devarashetty Shreya</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaudhry%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Aleeza Chaudhry</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Aleeza Chaudhry</span></h3>
<div class="p">
<sup>1</sup>
Internal Medicine, Monmouth Medical Center, Long Branch, USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaudhry%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aleeza Chaudhry</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sohini%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Sarkar Sohini</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Sarkar Sohini</span></h3>
<div class="p">
<sup>1</sup>
Internal Medicine, Monmouth Medical Center, Long Branch, USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sohini%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sarkar Sohini</span></a>
</div>
</div>
<sup>1</sup>
</div>
<div class="cg p">Editors: <span class="name western">Alexander Muacevic</span>, <span class="name western">John R Adler</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff-1">
<sup>1</sup>
Internal Medicine, Monmouth Medical Center, Long Branch, USA </div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">
FNU Arty <span>dr.fnu.arty22@gmail.com</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Accepted 2025 Jul 9; Collection date 2025 Jul.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025, Arty et al.</div>
<p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12333672  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40786355/" class="usa-link">40786355</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Heart failure with preserved ejection fraction (HFpEF) poses a growing public health challenge, characterized by limited therapeutic options and a high burden of comorbid obesity and type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown promise in addressing these comorbidities, offering potential benefits in obesity-related HFpEF. We analyzed key clinical trials, including SUSTAIN 6, PIONEER 6, STEP HFpEF, STEP HFpEF DM, and supportive studies on glucagon-like peptide receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, alongside mechanistic insights into semaglutide’s metabolic, anti-inflammatory, and decongestive effects. Data were drawn from randomized controlled trials, cohort studies, and pathophysiological reviews. Semaglutide significantly improves HFpEF outcomes in obese patients, with STEP HFpEF (n = 529) and STEP HFpEF DM (n = 616) demonstrating Kansas City Cardiomyopathy Questionnaire Clinical Summary Score increases of 16.6 and 13.7 points (vs. 8.7 and 6.4 with placebo, P &lt; 0.001), weight reductions of 13.3% and 9.8% (P &lt; 0.001), and 43.5% C-reactive protein reductions (P &lt; 0.001), all of which are clinically relevant in HFpEF management. SUSTAIN 6 and PIONEER 6 highlight cardiovascular safety in T2D, reducing stroke and mortality, while combination with SGLT2 inhibitors lowers HF exacerbations (HR 0.62). However, these findings are primarily derived from trials enrolling patients with obesity and relatively well-preserved renal and cardiac function, limiting applicability to the broader, heterogeneous HFpEF population. The included trials differed substantially in design: STEP trials focused on short-term, functional outcomes over 52 weeks; SUSTAIN 6 and PIONEER 6 assessed cardiovascular safety in T2D populations with varied HF status. Follow-up durations, primary endpoints, and inclusion criteria also varied across studies. This heterogeneity complicates direct comparison and limits the ability to draw firm conclusions about semaglutide’s effects on hard clinical endpoints such as hospitalization or mortality.</p>
<p>Semaglutide improves HFpEF symptoms by reducing visceral adiposity, systemic inflammation, and filling pressures, thereby enhancing exercise tolerance. These effects are primarily seen in obese patients with preserved renal and cardiac function and may not generalize to all HFpEF phenotypes. Semaglutide offers a novel therapeutic avenue for obese HFpEF patients, improving symptoms, function, and quality of life compared with existing therapies such as SGLT2 inhibitors, MRAs, and ARNIs. While cardiovascular benefits were established in T2D patients, cost-effectiveness remains a potential barrier to access and adherence, especially in lower-resource settings. Long-term trials, cost-effectiveness studies, and comparative analyses are needed to solidify its role in clinical practice, particularly across diverse HFpEF subgroups.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> clinical trials, glp-1 receptor agonist, heart failure management, heart failure with preserved ejection fraction, hfpef, obesity, ozempic, semaglutide</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction and background</h2>
<p>Heart failure with preserved ejection fraction (HFpEF) represents a growing public health challenge, characterized by a constellation of heart failure symptoms, including dyspnea, fatigue, and reduced exercise tolerance, despite a left ventricular ejection fraction (LVEF) of ≥50% [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. Unlike its counterpart, heart failure with reduced ejection fraction (HFrEF), which benefits from well-established pharmacological interventions such as beta-blockers, angiotensin-converting enzyme inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists, HFpEF remains a clinical enigma with fewer well-established treatment options, such as SGLT2 inhibitors and sacubitril/valsartan [<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. HFpEF accounts for approximately 50-60% of all heart failure cases worldwide, with an estimated 64 million individuals affected, a figure driven by an aging population and the rising prevalence of associated comorbidities including hypertension, coronary artery disease, obesity, type 2 diabetes (T2D), and chronic kidney disease (CKD) [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>]. These conditions not only amplify the incidence of HFpEF but also complicate its prognosis and management, underscoring the urgent need for novel therapeutic strategies.</p>
<p>Historically viewed as a diagnosis of exclusion, HFpEF has evolved into a recognized syndrome with distinct pathophysiological features, including elevated left ventricular (LV) filling pressures, diastolic dysfunction, left atrial (LA) enlargement, and often elevated natriuretic peptide (NP) levels [<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. However, its heterogeneity, spanning metabolic, inflammatory, and hemodynamic phenotypes, has hindered the development of universal diagnostic criteria and effective treatments [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. Obesity, present in over 80% of HFpEF patients, and T2D, affecting approximately 45%, are particularly prominent risk factors that exacerbate the condition through systemic inflammation, insulin resistance, and microvascular dysfunction [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. Despite their prevalence, these patient subgroups have been underrepresented in clinical trials, leaving a critical gap in understanding how best to address their unique contributions to HFpEF [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>]. Recent efforts have focused on more granular phenotyping through tools like the HFA-PEFF score and machine learning-based cluster analyses to facilitate individualized management. These tools offer a framework to better identify subpopulations, such as those with obesity or T2D, who may respond to targeted therapies. The therapeutic landscape for HFpEF has faced persistent challenges. Trials of agents successful in HFrEF, such as angiotensin receptor-neprilysin inhibitors (e.g., sacubitril/valsartan in PARAGON-HF) and spironolactone (TOPCAT trial), have yielded modest or inconsistent benefits in HFpEF, failing to significantly reduce mortality or comprehensively alleviate symptoms [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. SGLT2 inhibitors, such as dapagliflozin and empagliflozin, have recently shown promise in reducing heart failure events across a spectrum of ejection fractions (EMPEROR-Preserved, DELIVER), yet their impact on symptom burden, exercise capacity, and quality of life in obesity- or T2D-related HFpEF remains limited [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. These agents primarily provide cardiorenal and hemodynamic benefits through natriuresis and improved LV loading but have limited efficacy in weight loss and reversing systemic inflammation, which play a primary role in the pathophysiology of HFpEF.</p>
<p>Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as a compelling candidate to address these unmet needs. Initially developed for T2D management, semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon release, and promotes weight loss through appetite suppression and delayed gastric emptying [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. Its approval by the U.S. Food and Drug Administration (FDA) for chronic weight management (2.4 mg weekly subcutaneous dose) in adults with obesity or overweight with weight-related comorbidities, such as hypertension, T2D, or dyslipidemia, reflects its efficacy in achieving substantial weight reduction, with trials demonstrating losses of up to 13.3% of body weight [<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>]. Semaglutide, through its effects on insulin resistance, systemic inflammation, and visceral adiposity, directly targets the key pathophysiological mechanisms underpinning HFpEF, particularly in patients with obesity and T2D. Studies have shown a 43.5% reduction in C-reactive protein (CRP), and improvement in exercise capacity and quality of life in HFpEF [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>,<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]. HFpEF exhibits significant demographic variability, with women, who comprise the majority of patients, often presenting with greater symptom burden, more severe diastolic dysfunction, and unique cardiometabolic profiles that may influence semaglutide response. Differences in age, race, and body composition may also affect GLP-1 RA safety and efficacy, highlighting the need for more representative trials and subgroup analyses. While preliminary data are encouraging, larger long-term randomized clinical trials are needed to support these findings. Potential adverse effects such as gastrointestinal intolerance, volume depletion, and serious side effects such as pancreatitis and gallbladder disease should be considered, particularly in the elderly population. Contraindications such as a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 also limit its use in select populations.</p>
<p>This review article aims to synthesize the emerging evidence on semaglutide’s application in HFpEF, focusing on its mechanisms of action, outcomes from key clinical trials, and potential to reshape clinical practice. By addressing the metabolic, inflammatory, and hemodynamic drivers of HFpEF, semaglutide offers a novel therapeutic avenue, potentially bridging the gap between patient-centered outcomes (e.g., symptom relief, improved quality of life) and cardiovascular risk reduction. The following sections will explore the background of HFpEF, semaglutide’s pharmacological profile, and the clinical data supporting its use, culminating in a discussion of its implications and future directions.</p>
<p>Epidemiology and burden of HFpEF </p>
<p>The prevalence of HFpEF has grown substantially over recent decades, reflecting demographic shifts, rising life expectancy, and increasing cardiometabolic risk. Current estimates indicate that HFpEF represents half or more of all HF cases globally, and this proportion is expected to rise, particularly in regions where obesity rates are projected to approach 50% by 2030 [<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>,<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. HFpEF disproportionately affects older adults, women, and individuals with obesity or metabolic disease, populations that present with distinct clinical profiles and may respond differently to therapies [<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>]. Unlike heart failure with reduced ejection fraction, where survival has improved with guideline-directed medical therapy, HFpEF patients face a persistently high mortality risk, with 5-year survival rates hovering around 50% post-hospitalization [<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>]. This disparity reflects both the complexity of HFpEF and the paucity of effective interventions.</p>
<p>Subgroup analyses from large trials (e.g., PARAGON-HF, TOPCAT) have provided insight into potential responders to therapies like sacubitril/valsartan and spironolactone, but overall effects on mortality or sustained symptom relief have been modest [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. More recently, SGLT2 inhibitors such as dapagliflozin (DELIVER) and empagliflozin (EMPEROR-Preserved) have shown reductions in HF hospitalizations across the LVEF spectrum [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. However, their efficacy in symptom relief, exercise capacity, and metabolic modulation in patients with obesity-related HFpEF remains constrained. These limitations underscore the need for phenotype-specific therapeutic strategies that go beyond hemodynamic control.</p>
<p>The pie chart in Figure <a href="#FIG1" class="usa-link">1</a> illustrates the high prevalence of obesity (&gt;80%) and T2D (~45%) in HFpEF patients, alongside other common comorbidities such as hypertension, coronary artery disease (CAD), and CKD. Percentages reflect prevalence with potential overlap, as patients may have multiple comorbidities [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>,<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>].</p>
<figure class="fig xbox font-sm" id="FIG1"><h3 class="obj_head">Figure 1. Prevalence of comorbidities in heart failure with preserved ejection fraction .</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i01.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/c704b20f42f3/cureus-0017-00000087605-i01.jpg" loading="lazy" height="536" width="750" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>High prevalence of obesity (&gt;80%) and type 2 diabetes (T2D, ~45%) in HFpEF patients, alongside other common comorbidities such as hypertension, coronary artery disease (CAD), and chronic kidney disease (CKD).</p>
<p>Figure created by authors using the data from refs [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>,<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>].</p></figcaption></figure><p>Pathophysiology and heterogeneity </p>
<p>Heart failure with preserved ejection fraction (HFpEF) is not a single disease, but a complex condition involving multiple underlying causes and a wide range of clinical features. Core features include impaired left ventricular relaxation and increased stiffness, leading to elevated filling pressures during diastole, particularly under stress (e.g., exercise) [<a href="#REF21" class="usa-link" aria-describedby="REF21">21</a>]. These abnormalities are often accompanied by left ventricular hypertrophy, left atrial dilation, and subtle systolic dysfunction despite preserved ejection fraction, as well as extracardiac manifestations such as pulmonary hypertension and skeletal muscle impairment [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]. Elevated NPs, such as B-type NP (BNP), are common but not universal, complicating diagnosis in obese patients where NP production and clearance are altered [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>]. The understanding of HFpEF has evolved significantly over the past decade. Early definitions relied heavily on ejection fraction as a distinguishing feature from HFrEF, an oversimplification that ignored underlying mechanisms [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]. Contemporary frameworks, informed by studies like those of Shah et al., emphasize phenotyping based on clinical, imaging, laboratory, and molecular data [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>]. For instance, Fayol et al. classified HFpEF into three etiologic subgroups: idiopathic (dominated by non-cardiac comorbidities), secondary (linked to myocardial hemodynamic abnormalities), and metabolic (characterized by obesity, T2D, and severe diastolic dysfunction), with prognosis worsening across these categories [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]. The metabolic phenotype, marked by a fourfold increased mortality risk, underscores the pivotal role of obesity and T2D in driving adverse outcomes [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>].</p>
<p>Obesity contributes to HFpEF through multiple pathways. Excess visceral adipose tissue promotes a chronic inflammatory state, with macrophage infiltration releasing cytokines (e.g., interleukin-6, tumor necrosis factor-alpha) that impair endothelial nitric oxide bioavailability and increase myocardial stiffness via reduced cyclic GMP and protein kinase G activity [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. This inflammatory cascade exacerbates coronary microvascular dysfunction, a key feature of HFpEF, and elevates plasma volume and cardiac workload [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>]. T2D amplifies these effects through hyperglycemia, lipotoxicity, and hyperinsulinemia, which foster advanced glycation end-products, concentric left ventricular remodeling, and diabetic cardiomyopathy, a restrictive phenotype prevalent in HFpEF [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. The interplay of these factors results in a vicious cycle of hemodynamic stress, exercise intolerance, and symptom exacerbation, particularly in obese diabetic patients [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>].</p>
<p>The flowchart in Figure <a href="#FIG2" class="usa-link">2</a> illustrates the cascade from obesity and T2D to HFpEF syndrome through inflammation, endothelial dysfunction, microvascular disease, and left ventricular (LV) stiffness, resulting in clinical outcomes such as dyspnea, reduced six-minute walk test (6MWT) distance, and increased hospitalizations. Light blue arrows indicate detrimental pathways.</p>
<figure class="fig xbox font-sm" id="FIG2"><h3 class="obj_head">Figure 2. Pathophysiological mechanisms in obese HFpEF.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i02.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/4775e2669534/cureus-0017-00000087605-i02.jpg" loading="lazy" height="328" width="750" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>HFpEF: heart failure with preserved ejection fraction.</p></figcaption></figure><p>Clinical challenges and therapeutic gaps </p>
<p>Diagnosing HFpEF remains challenging due to its heterogeneity and overlap with other conditions (e.g., pulmonary disease, obesity-related dyspnea). The H2FPEF score and updated ESC guidelines have improved diagnostic precision by integrating clinical and echocardiographic parameters, yet many patients remain undiagnosed until advanced stages [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>,<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]. Therapeutically, HFpEF has proven resistant to strategies effective in HFrEF. The PARAGON-HF trial of sacubitril/valsartan showed a modest reduction in heart failure hospitalizations but no significant mortality benefit [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Spironolactone, evaluated in TOPCAT, improved cardiac structure but failed to reduce overall mortality, with benefits limited to specific subgroups [<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. Beta-blockers and angiotensin-converting enzyme (ACE) inhibitors, cornerstones of HFrEF management, lack consistent efficacy in HFpEF, reflecting differences in underlying pathophysiology [<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>]. SGLT2 inhibitors have recently offered hope, with the DELIVER and EMPEROR-Preserved trials demonstrating reductions in composite endpoints of worsening heart failure or cardiovascular death in patients with LVEF &gt;40% [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. However, their effects on symptom burden and obesity-specific outcomes are less pronounced, and their mechanism, primarily natriuretic and decongestive, does not fully address the metabolic and inflammatory drivers of HFpEF [<a href="#REF33" class="usa-link" aria-describedby="REF33">33</a>]. Weight loss, a proven benefit in obese HFpEF patients, improves exercise capacity and quality of life, as shown in trials of caloric restriction and exercise, yet achieving and sustaining it through lifestyle alone is challenging [<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>]. This gap has fueled interest in pharmacological agents like semaglutide, which combine weight reduction with metabolic and cardiovascular benefits.</p>
<p>Figure <a href="#FIG3" class="usa-link">3</a> shows the timeline tracking major therapeutic milestones in HFpEF management, from early therapies (beta-blockers, angiotensin-converting enzyme inhibitors (ACEi)) to recent advances (sodium-glucose cotransporter-2 inhibitors (SGLT2i), semaglutide). Outcomes reflect key findings: limited efficacy for beta-blockers/ACEi [<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>], modest benefits for spironolactone (TOPCAT, 2014) [<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>], neutral results for sacubitril/valsartan (PARAGON-HF, 2019) [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>], reduced heart failure (HF) events for SGLT2i (DELIVER/EMPEROR-Preserved, 2021-2022) [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>], and improved quality of life (QoL), weight loss, C-reactive protein (CRP) reduction, and 6-minute walk test (6MWT) distance with semaglutide (STEP HFpEF, 2023) [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>].</p>
<figure class="fig xbox font-sm" id="FIG3"><h3 class="obj_head">Figure 3. Evolution of HFpEF therapies and semaglutide's emergence.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i03.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/5308fc994474/cureus-0017-00000087605-i03.jpg" loading="lazy" height="177" width="750" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Figure created by authors using data from refs [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>-<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>,<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>].</p>
<p>HFpEF: heart failure with preserved ejection fraction.</p></figcaption></figure><p>Rationale for semaglutide in HFpEF </p>
<p>Semaglutide’s potential in HFpEF stems from its ability to target the syndrome’s metabolic and inflammatory roots. Approved for T2D (0.25-1 mg weekly subcutaneous or 3-14 mg daily oral) and obesity (2.4 mg weekly), it induces significant weight loss (e.g., 6-13.3% in STEP trials), improves glycemic control, and reduces cardiovascular events (e.g., stroke in SUSTAIN 6) without hypoglycemia risk [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>-<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. Its anti-inflammatory effects, evidenced by a 43.5% CRP reduction in HFpEF trials, address endothelial dysfunction and myocardial stiffness, while reduced diuretic needs suggest decongestive potential [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF35" class="usa-link" aria-describedby="REF35">35</a>]. These properties align with HFpEF’s obesity-driven phenotype, where visceral fat, inflammation, and insulin resistance predominate, and offer a counterbalance to the limited efficacy of traditional therapies. Moreover, patient priorities, symptom relief, and functional improvement may be better met by semaglutide’s broad actions, as formal interviews indicate these clinical outcomes rival survival in importance [<a href="#REF36" class="usa-link" aria-describedby="REF36">36</a>]. This background sets the stage for a detailed exploration of semaglutide’s mechanisms and clinical evidence in HFpEF. </p></section><section id="sec2"><h2 class="pmc_sec_title">Review</h2>
<p>Mechanism of action</p>
<p>Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), exerts a multifaceted mechanism of action that aligns with the metabolic, inflammatory, and hemodynamic challenges of heart failure with preserved ejection fraction (HFpEF), particularly in patients with obesity and T2D [<a href="#REF37" class="usa-link" aria-describedby="REF37">37</a>]. Designed for prolonged activity, semaglutide incorporates structural modifications to resist degradation and allow once-weekly subcutaneous dosing or daily oral formulations, improving patient adherence and long-term tolerability [<a href="#REF38" class="usa-link" aria-describedby="REF38">38</a>-<a href="#REF40" class="usa-link" aria-describedby="REF40">40</a>].</p>
<p>Metabolic effects</p>
<p>Semaglutide’s primary metabolic actions stem from its agonism of GLP-1 receptors, widely expressed in pancreatic β-cells, the gastrointestinal tract, and the central nervous system. It enhances glucose-dependent insulin secretion, suppresses glucagon release during hyperglycemia, and inhibits hepatic gluconeogenesis, collectively lowering blood glucose and HbA1c without risking hypoglycemia, a critical advantage over traditional antidiabetic agents in HFpEF patients prone to comorbidities [<a href="#REF41" class="usa-link" aria-describedby="REF41">41</a>,<a href="#REF42" class="usa-link" aria-describedby="REF42">42</a>]. In T2D, these effects mitigate hyperglycemia-induced lipotoxicity and advanced glycation end-products, which contribute to microvascular dysfunction and myocardial stiffness in HFpEF [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. Clinical trials, such as SUSTAIN, report HbA1c reductions of 1.5-1.8% with semaglutide, underscoring its potency [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>].</p>
<p>Weight loss and appetite regulation</p>
<p>Beyond glycemic control, semaglutide induces significant weight loss, a pivotal benefit for obese HFpEF patients. It delays gastric emptying, enhancing satiety, and acts on hypothalamic and brainstem appetite centers via vagal nerve pathways and direct central nervous system effects, reducing energy intake [<a href="#REF43" class="usa-link" aria-describedby="REF43">43</a>]. The Semaglutide Treatment Effect in People with Obesity (STEP) trials demonstrated average weight reductions of 6% by week 12 and 12-13.3% by weeks 28-52 with a 2.4 mg weekly dose, far exceeding outcomes with lifestyle interventions alone [<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>].</p>
<p>Anti-inflammatory and cardiovascular effects</p>
<p>Semaglutide’s anti-inflammatory properties further enhance its relevance to HFpEF. Obesity and T2D foster a pro-inflammatory state, with adipose tissue macrophages releasing cytokines (e.g., IL-6, TNF-α) that impair endothelial nitric oxide (NO) bioavailability, reduce cyclic GMP and protein kinase G activity, and increase myocardial stiffness [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. In the STEP HFpEF trials, semaglutide reduced C-reactive protein (CRP) by 43.5% compared to 7.3% with placebo (P &lt; 0.001) [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]. This level of CRP reduction is comparable to anti-inflammatory interventions associated with improved cardiovascular outcomes and may reflect a meaningful attenuation of systemic and myocardial inflammation. Such reductions may also improve endothelial function, coronary microvascular perfusion, and interstitial remodeling, core pathophysiologic mechanisms in HFpEF. While semaglutide demonstrated cardiovascular benefits in SUSTAIN 6 by reducing stroke risk, PIONEER 6 showed a non-significant trend toward reduced cardiovascular death [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>,<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. Whether these benefits are unique to semaglutide or reflect a broader GLP-1 RA class effect remains under investigation, although head-to-head data suggest comparable metabolic effects across agents, with variability in cardiovascular endpoints.</p>
<p>Hemodynamic and decongestive potential</p>
<p>Emerging evidence suggests that semaglutide may influence fluid dynamics in HFpEF. The STEP HFpEF analysis presented at Heart Failure 2024 reported a reduced need for loop diuretics, a lower average diuretic dose, and a higher likelihood of diuretic de-escalation compared to placebo [<a href="#REF35" class="usa-link" aria-describedby="REF35">35</a>]. While the precise mechanism remains speculative, it is possibly related to weight loss, reducing plasma volume, improved renal hemodynamics, and potential neurohormonal modulation. This finding positions semaglutide as a potential adjunct to traditional decongestive strategies, addressing a critical aspect of HFpEF management [<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>].</p>
<p>In summary, semaglutide’s mechanisms, including metabolic optimization, weight reduction, anti-inflammatory action, and possible decongestive effects, directly target the obesity-driven, inflammatory, and hemodynamic hallmarks of HFpEF (Figure <a href="#FIG4" class="usa-link">4</a>). These properties distinguish it from existing therapies like SGLT2 inhibitors, which primarily address fluid overload, and provide a rationale for its evaluation in this population. </p>
<figure class="fig xbox font-sm" id="FIG4"><h3 class="obj_head">Figure 4. Mechanism of action of semaglutide in HFpEF.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i04.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/94a5f9527b58/cureus-0017-00000087605-i04.jpg" loading="lazy" height="436" width="750" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>HFpEF: heart failure with preserved ejection fraction.</p></figcaption></figure><p>Key clinical trials</p>
<p>The clinical evidence supporting semaglutide in heart failure with preserved ejection fraction (HFpEF) and related conditions derives from a series of robust trials, ranging from cardiovascular outcome studies in T2D to targeted investigations in HFpEF with obesity and T2D. Below, we review the pivotal trials, SUSTAIN 6, PIONEER 6, STEP HFpEF, STEP HFpEF DM, JACC Study, and SUMMIT, focusing on their design, outcomes, and implications for HFpEF.</p>
<p>SUSTAIN 6: semaglutide and cardiovascular outcomes in T2D</p>
<p>The SUSTAIN 6 trial enrolled 3,297 patients with T2D and high cardiovascular risk (83% with established cardiovascular or kidney disease), randomizing them to semaglutide (0.5 or 1.0 mg weekly) or placebo for 104 weeks [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. The primary endpoint, which is the first occurrence of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke, demonstrated semaglutide’s non-inferiority and superiority. Nonfatal stroke occurred in 1.6% of the semaglutide group vs. 2.7% of placebo (HR 0.61, 95% CI 0.38-0.99, P = 0.04), while nonfatal MI showed a trend toward reduction (2.9% vs. 3.9%, HR 0.74, 95% CI 0.51-1.08, P = 0.12). Cardiovascular death rates were similar (2.7% vs. 2.8%). Gastrointestinal side effects (e.g., nausea, vomiting) were more common with semaglutide, but overall safety was favorable [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. While not HFpEF-specific, these findings established semaglutide’s cardiovascular benefits, laying the groundwork for its exploration in heart failure populations with overlapping risk profiles.</p>
<p>PIONEER 6: oral semaglutide and cardiovascular outcomes in T2D</p>
<p>PIONEER 6 assessed oral semaglutide in 3,183 patients with T2D and high cardiovascular risk over a median of 15.9 months [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. Participants received oral semaglutide (up to 14 mg daily) or placebo, with the primary endpoint being major adverse cardiovascular events (MACE): cardiovascular death, nonfatal MI, or nonfatal stroke. MACE rates were 3.8% with semaglutide vs. 4.8% with placebo (HR 0.79, 95% CI 0.57-1.11, P &lt; 0.001 for non-inferiority), with significant reductions in cardiovascular death (0.9% vs. 1.9%, HR 0.49, 95% CI 0.27-0.92) and all-cause mortality (1.4% vs. 2.8%, HR 0.51, 95% CI 0.31-0.84). The trial confirmed oral semaglutide’s safety and efficacy, broadening its applicability, though HFpEF-specific outcomes were not evaluated [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. These results reinforce semaglutide’s potential to mitigate cardiovascular risk factors prevalent in HFpEF, such as atherosclerosis and metabolic dysfunction.</p>
<p>STEP HFpEF: semaglutide in obesity-related HFpEF</p>
<p>The STEP HFpEF trial was a landmark double-blind, randomized study of 529 patients with HFpEF (EF ≥45%) and obesity (BMI ≥30), assigned to semaglutide 2.4 mg weekly or placebo for 52 weeks [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]. The primary endpoint, that is, the change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), improved significantly with semaglutide (+16.6 points) vs. placebo (+8.7 points), with a between-group difference of 7.8 points (P &lt; 0.001), exceeding the 5-point threshold for a clinically meaningful improvement in symptoms and quality of life. Secondary endpoints included weight reduction (−13.3% vs. −2.6%, P &lt; 0.001), increased 6-minute walk test (6MWT) distance (+21.5 meters vs. +1.2 meters, P &lt; 0.001), and a 43.5% vs. 7.3% reduction in CRP (P &lt; 0.001). Serious adverse events were less frequent with semaglutide (13.3% vs. 26.7%), though gastrointestinal side effects led to discontinuation in some cases [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]. Semaglutide’s impact on inflammation and weight reduction may address central HFpEF pathophysiologic mechanisms such as myocardial stiffness, vascular dysfunction, and exercise intolerance. CRP reduction suggests attenuation of systemic inflammation, a known contributor to HFpEF progression. These mechanistic effects align with the observed clinical benefits in symptoms and functional capacity, helping to close a critical therapeutic gap in obesity-related HFpEF, as shown in Figure <a href="#FIG2" class="usa-link">2</a>.</p>
<p>STEP HFpEF DM: semaglutide in HFpEF with T2D</p>
<p>The STEP HFpEF DM trial extended these findings to 616 patients with HFpEF (EF ≥45%), obesity (BMI ≥30), and T2D, randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks across 108 sites [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. The KCCQ-CSS increased by 13.7 points with semaglutide vs. 6.4 points with placebo (difference 7.3, P &lt; 0.001), with weight loss of 9.8% vs. 3.4% (P &lt; 0.001) and 6MWT gains of 14.3 meters (P = 0.008). CRP reduction mirrored STEP HFpEF (43.5%, P &lt; 0.001), and serious adverse events were lower (17.7% vs. 28.8%). The hierarchical composite endpoint (death, HF events, KCCQ-CSS, and 6MWT) favored semaglutide (win ratio 1.58, P &lt; 0.001), reinforcing its efficacy in this dual-comorbidity cohort [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. The slightly lower weight loss compared to STEP HFpEF may reflect T2D-related metabolic differences, but the benefits across symptom, function, and inflammation domains remained robust.</p>
<p>Figure <a href="#FIG5" class="usa-link">5</a> shows the bar graph comparing semaglutide vs. placebo effects on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS, points), weight loss (%), 6-minute walk test (6MWT) distance (meters), and C-reactive protein (CRP) reduction (%) in the STEP HFpEF (n = 529) and STEP HFpEF DM (n = 616) trials. Error bars represent standard deviation. P-values indicate statistical significance. Dashed line at 5 points denotes the clinical significance threshold for KCCQ-CSS [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>].</p>
<figure class="fig xbox font-sm" id="FIG5"><h3 class="obj_head">Figure 5. Semaglutide outperforms placebo in STEP HFpEF trials.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i05.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/99d31a62b4b1/cureus-0017-00000087605-i05.jpg" loading="lazy" height="415" width="750" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Bar chart created by the authors using data from refs [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>].</p>
<p>HFpEF: heart failure with preserved ejection fraction, STEP: Semaglutide Treatment Effect in People With Obesity.</p></figcaption></figure><p>Table <a href="#TAB1" class="usa-link">1</a> compares the key aspects and outcomes of the STEP-HFpEF and STEP-HFpEF DM trials, which evaluated the effects of semaglutide 2.4 mg once weekly in obese patients with heart failure with preserved ejection fraction (HFpEF), with and without T2D.</p>
<section class="tw xbox font-sm" id="TAB1"><h3 class="obj_head">Table 1. A summary of STEP-HFpEF and STEP-HFpEF DM trials.</h3>
<div class="caption p">
<p>Table created by the authors using data from refs [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>].</p>
<p>HFpEF: heart failure with preserved ejection fraction, STEP: Semaglutide Treatment Effect in People With Obesity.</p>
</div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Aspect</td>
<td rowspan="1" colspan="1">STEP-HFpEF</td>
<td rowspan="1" colspan="1">STEP-HFpEF DM</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Population type</td>
<td rowspan="1" colspan="1">Obese patients with HFpEF (without type 2 diabetes)</td>
<td rowspan="1" colspan="1">Obese patients with HFpEF and type 2 diabetes</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Dose</td>
<td rowspan="1" colspan="1">Semaglutide 2.4 mg once weekly</td>
<td rowspan="1" colspan="1">Semaglutide 2.4 mg once weekly</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Endpoints</td>
<td rowspan="1" colspan="1">Symptom improvement: Kansas City Cardiomyopathy Questionnaire Symptom Improvement (KCCQ-CSS Clinical Summary Score</td>
<td rowspan="1" colspan="1">Symptom improvement: KCCQ-CSS Clinical Summary Score</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">Weight loss</td>
<td rowspan="1" colspan="1">Weight loss</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">Inflammatory Markers: C-reactive protein (CRP) reduction  </td>
<td rowspan="1" colspan="1">Inflammatory markers: C-reactive protein (CRP) reduction  </td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Clinical effects</td>
<td rowspan="1" colspan="1">Symptom improvement: +16.6 points in KCCQ-CSS  </td>
<td rowspan="1" colspan="1">Symptom improvement: +13.7 points in KCCQ- Effects CSS  </td>
</tr>
<tr>
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">Functional gains: +21.5 meters in 6MWT  </td>
<td rowspan="1" colspan="1">Functional gains: +12.7 meters in 6MWT  </td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">Weight loss: -13.3% body weight  </td>
<td rowspan="1" colspan="1">Weight loss: -9.8% body weight  </td>
</tr>
<tr>
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">CRP reduction: -43.5%  </td>
<td rowspan="1" colspan="1">CRP reduction: -43.5%  </td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1"> </td>
<td rowspan="1" colspan="1">Safety/adverse effects: well-tolerated with no significant safety concerns</td>
<td rowspan="1" colspan="1">Safety/adverse effects: well-tolerated with no significant safety concerns  </td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>JACC study: GLP-1 RA with SGLT2 inhibitors in HFpEF</p>
<p>A retrospective cohort study analyzed 29,922 patients with T2D and obesity-related HFpEF on SGLT2 inhibitors, comparing 7,044 patients who received additional GLP-1 RA therapy (including semaglutide) with 7,044 on SGLT2 inhibitors alone over 12 months [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]. Combination therapy reduced HF exacerbations (HR 0.62, 95% CI 0.58-0.67), all-cause mortality (HR 0.64, 95% CI 0.54-0.75), and hospitalizations (HR 0.74, 95% CI 0.71-0.78), alongside lower risks of atrial fibrillation, pulmonary hypertension, and renal injury. Importantly, the combination was associated with an elevated risk of diabetic retinopathy, an established complication of rapid glycemic improvement with GLP-1 RAs. This underscores the need for baseline retinal screening and gradual glycemic control [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]. While not exclusively semaglutide-focused, this study suggests synergistic benefits with SGLT2 inhibitors, a class already established in HFpEF-enhancing the case for combination strategies.</p>
<p>SUMMIT trial: tirzepatide as a comparator</p>
<p>The SUMMIT trial, while not semaglutide-specific, provides context by evaluating tirzepatide (a dual GLP-1/GIP agonist) in 731 obese HFpEF patients (EF ≥50%) over 104 weeks [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]. Tirzepatide (up to 15 mg weekly) reduced cardiovascular death or worsening HF (9.9% vs. 15.3%, HR 0.62, P = 0.026) and improved KCCQ-CSS (19.5 vs. 12.7 points, P &lt; 0.001) compared to placebo, though gastrointestinal discontinuation rates were higher (6.3% vs. 1.4%) [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]. These findings parallel semaglutide’s benefits, suggesting a class effect of incretin-based therapies in HFpEF, with tirzepatide’s dual agonism potentially offering incremental advantages.</p>
<p>Across these trials, KCCQ-CSS improvements and hazard ratios for cardiovascular events provide a comparative lens on therapeutic efficacy. Tirzepatide demonstrated the greatest symptomatic improvement (KCCQ-CSS gain of 6.8 points over placebo), while the GLP-1 RA + SGLT2i combination yielded strong prognostic benefits, including a 36% relative risk reduction in heart failure events. These findings suggest both additive and potentially complementary effects of metabolic therapies in HFpEF. Of note, EF inclusion thresholds varied (≥45% in STEP and JACC studies vs. ≥50% in SUMMIT), which may influence generalizability. Patients with EF between 45-50%, often excluded from stricter HFpEF trials, represent a transitional group that may benefit similarly, though further stratified analyses are needed.</p>
<p>Table <a href="#TAB2" class="usa-link">2</a> provides a comparative summary of these trials, synthesizing their designs, outcomes, and limitations.</p>
<section class="tw xbox font-sm" id="TAB2"><h3 class="obj_head">Table 2. Comparative summary of key clinical trials evaluating semaglutide and related therapies in HFpEF and related conditions.</h3>
<div class="caption p">
<p>Table created by the authors using the data from refs [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>,<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>-<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>].</p>
<p>T2D: type 2 diabetes, CV: cardiovascular, MI: myocardial infarction, MACE: major adverse cardiovascular events, HFpEF: heart failure with preserved ejection fraction, EF: ejection fraction, BMI: body mass index, KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, CRP: C-reactive protein, GLP-1 RA: glucagon-like peptide-1 receptor agonist, SGLT2: sodium-glucose cotransporter 2, GIP: glucose-dependent insulinotropic polypeptide, GI: gastrointestinal.</p>
</div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Study</td>
<td rowspan="1" colspan="1">Population</td>
<td rowspan="1" colspan="1">Intervention</td>
<td rowspan="1" colspan="1">Primary Endpoint</td>
<td rowspan="1" colspan="1">Key Findings</td>
<td rowspan="1" colspan="1">Limitations</td>
<td rowspan="1" colspan="1">References</td>
</tr>
<tr>
<td rowspan="1" colspan="1">SUSTAIN 6</td>
<td rowspan="1" colspan="1">3,297 T2D patients with high CV risk (83% with established CV or kidney disease)</td>
<td rowspan="1" colspan="1">Semaglutide 0.5–1.0 mg weekly vs. placebo</td>
<td rowspan="1" colspan="1">CV death, nonfatal MI, nonfatal stroke (MACE)</td>
<td rowspan="1" colspan="1">- Reduced nonfatal stroke (HR 0.61, P=0.04) - Trend toward reduction in nonfatal MI (HR 0.74, P=0.12) - No effect on CV death</td>
<td rowspan="1" colspan="1">- Not HFpEF-specific - Short follow-up (104 weeks) - Focused on CV events, not HFpEF-specific endpoints</td>
<td rowspan="1" colspan="1">Marso et al. (2016) [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>].</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">PIONEER 6</td>
<td rowspan="1" colspan="1">3,183 T2D patients with high CV risk</td>
<td rowspan="1" colspan="1">Oral semaglutide up to 14 mg daily vs. placebo</td>
<td rowspan="1" colspan="1">Major adverse CV events (MACE: CV death, nonfatal MI, nonfatal stroke)</td>
<td rowspan="1" colspan="1">- Non-inferiority for MACE (HR 0.79, P&lt;0.001) - Significant reduction in CV death (HR 0.49, P=0.01) and all-cause mortality (HR 0.51, P&lt;0.001)</td>
<td rowspan="1" colspan="1">- No HFpEF-specific outcomes - Short follow-up (~16 months) - Focused on MACE, not HFpEF-specific symptoms or function</td>
<td rowspan="1" colspan="1">Husain et al. (2019) [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]</td>
</tr>
<tr>
<td rowspan="1" colspan="1">STEP HFpEF</td>
<td rowspan="1" colspan="1">529 obese HFpEF patients (EF ≥45%), BMI ≥30</td>
<td rowspan="1" colspan="1">Semaglutide 2.4 mg weekly vs. placebo</td>
<td rowspan="1" colspan="1">Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ- CSS)</td>
<td rowspan="1" colspan="1">- Improved KCCQ-CSS (+16.6 vs. +8.7, P&lt;0.001) - 13.3% weight loss vs. 2.6% with placebo (P&lt;0.001) - 43.5% reduction in CRP (P&lt;0.001)</td>
<td rowspan="1" colspan="1">- No data on hard endpoints (e.g., HF hospitalizations) - 1- year follow-up - Focused on obese patients, limiting applicability to non-obese HFpEF</td>
<td rowspan="1" colspan="1">Kosiborod et al. (2023) [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]  </td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">STEP HFpEF DM</td>
<td rowspan="1" colspan="1">616 obese HFpEF patients with T2D (EF ≥45%), BMI ≥30</td>
<td rowspan="1" colspan="1">Semaglutide 2.4 mg weekly vs. placebo</td>
<td rowspan="1" colspan="1">Change in KCCQ- CSS</td>
<td rowspan="1" colspan="1">- KCCQ-CSS increase of 13.7 points vs. 6.4 with placebo (P&lt;0.001) - 9.8% weight loss vs. 3.4% with placebo (P&lt;0.001) - 43.5% CRP reduction (P&lt;0.001)</td>
<td rowspan="1" colspan="1">- No assessment of long-term outcomes (e.g., HF hospitalizations) - Focus on patients with T2D, differing from non-diabetic HFpEF - 1- year follow-up</td>
<td rowspan="1" colspan="1">Kosiborod et al, (2024) [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]</td>
</tr>
<tr>
<td rowspan="1" colspan="1">JACC Study</td>
<td rowspan="1" colspan="1">29,922 T2D, obese HFpEF patients on SGL2 inhibitors (7,044 with GLP-1 RA vs. 7,044 without)</td>
<td rowspan="1" colspan="1">GLP-1 RA (including semaglutide) + SGLT2 inhibitors vs. SGLT2 inhibitors alone</td>
<td rowspan="1" colspan="1">HF exacerbations, all-cause mortality, hospitalizations</td>
<td rowspan="1" colspan="1">- Reduced HF exacerbations (HR 0.62), hospitalizations (HR 0.74), and all-cause mortality (HR 0.64)</td>
<td rowspan="1" colspan="1">- Retrospective study - Increased risk of diabetic retinopathy with combination therapy</td>
<td rowspan="1" colspan="1">Patel et al, (2024) [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">SUMMIT Trial</td>
<td rowspan="1" colspan="1">731 obese HFpEF patients (EF ≥50%)</td>
<td rowspan="1" colspan="1">Tirzepatide (GLP-1/GIP agonist) up to 15 mg weekly vs. placebo</td>
<td rowspan="1" colspan="1">CV death or worsening HF</td>
<td rowspan="1" colspan="1">- Reduced CV death or worsening HF (HR 0.62, P=0.026) - Significant improvement in KCCQ-CSS (+19.5 vs. +12.7, P&lt;0.001)</td>
<td rowspan="1" colspan="1">- Focused on tirzepatide, not semaglutide - Higher GI discontinuation rates with tirzepatide</td>
<td rowspan="1" colspan="1">Packer et al, (2024) [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Discussion and clinical implications</p>
<p>Heart failure with preserved ejection fraction (HFpEF) poses a significant clinical burden, particularly in patients with obesity, who often experience more severe symptoms, reduced functional capacity, and poorer quality of life [<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>,<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>,<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>,<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]. Symptom relief and improved physical function are increasingly recognized as therapeutic priorities, on par with reducing mortality and hospitalizations [<a href="#REF36" class="usa-link" aria-describedby="REF36">36</a>]. However, conventional heart failure therapies have shown limited efficacy in achieving these goals in HFpEF. Trials such as TOPCAT, Aldo-DHF, and PARAGON-HF failed to demonstrate significant reductions in mortality, despite modest improvements in hospitalization rates and cardiac structure [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. Obesity-related HFpEF is characterized by distinct hemodynamic and inflammatory features, including volume overload, impaired NP signaling, and systemic inflammation [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>,<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>]. These factors complicate management and contribute to worse outcomes. While lifestyle interventions can improve functional status, pharmacologic options targeting this phenotype have been limited until recently [<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>].</p>
<p>Emerging therapies such as semaglutide, a GLP-1 receptor agonist, offer a novel, multifaceted approach. Beyond weight loss, semaglutide improves symptoms, exercise capacity, and inflammatory markers, addressing several key pathophysiologic mechanisms in obese HFpEF [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. In the STEP HFpEF and STEP HFpEF DM trials, semaglutide produced clinically meaningful increases in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), reduced C-reactive protein (CRP) by over 40%, and improved 6-minute walk distance. These effects are particularly notable given that even guideline-directed therapies such as SGLT2 inhibitors, spironolactone, or ARNI (e.g., sacubitril/valsartan) have shown more modest improvements in patient-reported outcomes [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>,<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>].</p>
<p>Semaglutide’s ability to target obesity, inflammation (via CRP), and metabolic dysfunction aligns well with a precision medicine approach, wherein therapy is tailored to distinct phenotypes within HFpEF. This precision approach is supported by identifiable clinical features such as elevated BMI, elevated inflammatory biomarkers (e.g., CRP), insulin resistance or T2D, and exercise intolerance. These parameters may help clinicians select patients most likely to benefit from semaglutide, and ongoing studies may refine biomarker-based treatment algorithms.</p>
<p>Semaglutide’s benefits complement those of SGLT2 inhibitors, suggesting a potential synergistic strategy that targets both congestion and metabolic dysfunction [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]. However, the study also noted an increased risk of diabetic retinopathy, a complication associated with rapid glucose lowering. As a result, clinicians should consider retinal screening prior to initiation of combination therapy. Compared to agents like tirzepatide, which showed cardiovascular benefits but higher rates of gastrointestinal side effects, semaglutide appears particularly effective in improving physical performance, an outcome highly valued by patients (Figure <a href="#FIG6" class="usa-link">6</a>) [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>].</p>
<figure class="fig xbox font-sm" id="FIG6"><h3 class="obj_head">Figure 6. Synergetic effects of semaglutide and SGL2 inhibitors.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333672_cureus-0017-00000087605-i06.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f4/12333672/db62285f670f/cureus-0017-00000087605-i06.jpg" loading="lazy" height="564" width="750" alt="Figure 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Image created by the authors using the data from ref [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>].</p></figcaption></figure><p>Despite the promising efficacy profile, real-world implementation of semaglutide remains challenging. Barriers include high cost, limited insurance coverage, and prescribing logistics, particularly in primary care settings. While semaglutide has been approved for obesity and diabetes, its role in HFpEF is still evolving and has not yet been incorporated into major heart failure guidelines. Reimbursement pathways often lag behind evidence, and disparities in access, especially among underserved populations, may widen existing healthcare gaps. Moreover, adherence may be compromised by gastrointestinal side effects, weekly injection burden, and out-of-pocket costs.</p>
<p>Trial limitations must also be acknowledged. In the STEP HFpEF trials, dropout rates due to adverse events, mainly gastrointestinal, were higher in the semaglutide arms. Additionally, while the trials were double-blind and placebo-controlled, the visible weight loss in treated patients may have compromised blinding, potentially influencing subjective endpoints such as KCCQ scores. Long-term data beyond 52 weeks, including on heart failure hospitalizations and mortality, are still awaited [<a href="#REF35" class="usa-link" aria-describedby="REF35">35</a>,<a href="#REF40" class="usa-link" aria-describedby="REF40">40</a>].</p>
<p>Limitations of STEP HFpEF trials</p>
<p>The STEP HFpEF trials, while groundbreaking, have several limitations that temper their interpretation and generalizability. First, their primary design focused on symptoms, physical limitations, and exercise function (KCCQ-CSS, 6MWT, weight loss), not clinical events such as heart failure hospitalizations or urgent visits. Second, the one-year follow-up duration restricts conclusions about long-term efficacy and safety. While semaglutide showed sustained improvements in KCCQ-CSS, 6MWT, and weight loss compared to placebo, the durability of these effects beyond 52 weeks remains unproven. Third, generalizability is constrained by the trials’ exclusive focus on obese HFpEF patients (BMI ≥30). This limits applicability to non-obese HFpEF phenotypes, e.g., those driven by hypertension or aging without significant adiposity, which may differ in pathophysiology and treatment response. Exclusion of non-diabetic patients in STEP HFpEF-DM further narrows relevance, as T2D alters metabolic and inflammatory profiles, potentially amplifying semaglutide’s effects. This phenotypic specificity reduces external validity, particularly for leaner or metabolically healthy HFpEF cohorts. These limitations highlight the need for larger, long-term studies to more comprehensively define the role of semaglutide across the spectrum of heart failure.</p></section><section id="sec3"><h2 class="pmc_sec_title">Conclusions</h2>
<p>STEP-HFpEF and STEP HFpEF-DM demonstrated semaglutide’s potential in improving symptoms, exercise capacity, inflammation, and weight among obese HFpEF patients-with or without T2D-while maintaining a favorable safety profile. While reduction in hospitalization was not assessed in the STEP trials, observational data suggest possible benefits in healthcare utilization. Additive effects with SGLT2 inhibitors are inferred from real-world retrospective data, though not yet confirmed in randomized trials. Semaglutide offers a promising metabolic approach for obesity-related HFpEF by improving patient-reported outcomes (KCCQ score, physical function), which are increasingly prioritized in HFpEF management. Future research should focus on long-term outcomes, head-to-head comparisons with other agents (e.g., tirzepatide, SGLT2is), and trials in the non-obese HFpEF population. Monitoring known risks such as gastrointestinal intolerance and diabetic retinopathy is essential, particularly in high-risk populations, to ensure safe implementation of semaglutide in heart failure management.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Disclosures</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Conflicts of interest:</strong> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p>
<p><strong>Payment/services info:</strong> All authors have declared that no financial support was received from any organization for the submitted work.</p>
<p><strong>Financial relationships:</strong> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p>
<p><strong>Other relationships:</strong> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p>
</div></div></section><section id="fn-group2" class="fn-group"><h2 class="pmc_sec_title">Author Contributions</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2">
<p><strong>Concept and design:</strong>  FNU Arty, Devarashetty Shreya, Aleeza Chaudhry </p>
<p><strong>Drafting of the manuscript:</strong>  FNU Arty, Devarashetty Shreya, Aleeza Chaudhry </p>
<p><strong>Critical review of the manuscript for important intellectual content:</strong>  FNU Arty, Devarashetty Shreya, Sarkar Sohini, Aleeza Chaudhry </p>
<p><strong>Acquisition, analysis, or interpretation of data:</strong>  Sarkar Sohini, Aleeza Chaudhry </p>
<p><strong>Supervision:</strong>  Sarkar Sohini</p>
</div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="REF1">
<span class="label">1.</span><cite>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. McDonagh TA, Metra M, Adamo M, et al.  Eur Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehab368" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34447992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=2021%20ESC%20Guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure&amp;volume=42&amp;publication_year=2021&amp;pages=3599-3726&amp;pmid=34447992&amp;doi=10.1093/eurheartj/ehab368&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF2">
<span class="label">2.</span><cite>Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Bozkurt B, Coats AJ, Tsutsui H, et al.  Eur J Heart Fail. 2021;23:352–380. doi: 10.1002/ejhf.2115.</cite> [<a href="https://doi.org/10.1002/ejhf.2115" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33605000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Universal%20definition%20and%20classification%20of%20heart%20failure:%20a%20report%20of%20the%20Heart%20Failure%20Society%20of%20America,%20Heart%20Failure%20Association%20of%20the%20European%20Society%20of%20Cardiology,%20Japanese%20Heart%20Failure%20Society%20and%20Writing%20Committee%20of%20the%20Universal%20Definition%20of%20Heart%20Failure:%20Endorsed%20by%20the%20Canadian%20Heart%20Failure%20Society,%20Heart%20Failure%20Association%20of%20India,%20Cardiac%20Society%20of%20Australia%20and%20New%20Zealand,%20and%20Chinese%20Heart%20Failure%20Association&amp;volume=23&amp;publication_year=2021&amp;pages=352-380&amp;pmid=33605000&amp;doi=10.1002/ejhf.2115&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF3">
<span class="label">3.</span><cite>Global public health burden of heart failure. Savarese G, Lund LH. Card Fail Rev. 2017;3:7–11. doi: 10.15420/cfr.2016:25:2.</cite> [<a href="https://doi.org/10.15420/cfr.2016:25:2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5494150/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28785469/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Card%20Fail%20Rev&amp;title=Global%20public%20health%20burden%20of%20heart%20failure&amp;volume=3&amp;publication_year=2017&amp;pages=7-11&amp;pmid=28785469&amp;doi=10.15420/cfr.2016:25:2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF4">
<span class="label">4.</span><cite>How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Pieske B, Tschöpe C, de Boer RA, et al.  Eur Heart J. 2019;40:3297–3317. doi: 10.1093/eurheartj/ehz641.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehz641" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31504452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=How%20to%20diagnose%20heart%20failure%20with%20preserved%20ejection%20fraction:%20the%20HFA-PEFF%20diagnostic%20algorithm:%20a%20consensus%20recommendation%20from%20the%20Heart%20Failure%20Association%20(HFA)%20of%20the%20European%20Society%20of%20Cardiology%20(ESC)&amp;volume=40&amp;publication_year=2019&amp;pages=3297-3317&amp;pmid=31504452&amp;doi=10.1093/eurheartj/ehz641&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF5">
<span class="label">5.</span><cite>Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity? Severino P, D'Amato A, Prosperi S, et al.  J Clin Med. 2022;11 doi: 10.3390/jcm11030857.</cite> [<a href="https://doi.org/10.3390/jcm11030857" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8836547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35160308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=Do%20the%20current%20guidelines%20for%20heart%20failure%20diagnosis%20and%20treatment%20fit%20with%20clinical%20complexity?&amp;volume=11&amp;publication_year=2022&amp;pmid=35160308&amp;doi=10.3390/jcm11030857&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF6">
<span class="label">6.</span><cite>Obese heart failure with preserved ejection fraction phenotype: from pariah to central player. Kitzman DW, Lam CS. Circulation. 2017;136:20–23. doi: 10.1161/CIRCULATIONAHA.117.028365.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.117.028365" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28674090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Obese%20heart%20failure%20with%20preserved%20ejection%20fraction%20phenotype:%20from%20pariah%20to%20central%20player&amp;volume=136&amp;publication_year=2017&amp;pages=20-23&amp;pmid=28674090&amp;doi=10.1161/CIRCULATIONAHA.117.028365&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF7">
<span class="label">7.</span><cite>Epidemiology of heart failure with preserved ejection fraction. Dunlay SM, Roger VL, Redfield MM. Nat Rev Cardiol. 2017;14:591–602. doi: 10.1038/nrcardio.2017.65.</cite> [<a href="https://doi.org/10.1038/nrcardio.2017.65" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28492288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cardiol&amp;title=Epidemiology%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=14&amp;publication_year=2017&amp;pages=591-602&amp;pmid=28492288&amp;doi=10.1038/nrcardio.2017.65&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF8">
<span class="label">8.</span><cite>Predicting heart failure with preserved and reduced ejection fraction: The International Collaboration on Heart Failure Subtypes. Ho JE, Enserro D, Brouwers FP, et al.  Circ Heart Fail. 2016;9 doi: 10.1161/CIRCHEARTFAILURE.115.003116.</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4902276/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27266854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=Predicting%20heart%20failure%20with%20preserved%20and%20reduced%20ejection%20fraction:%20The%20International%20Collaboration%20on%20Heart%20Failure%20Subtypes&amp;volume=9&amp;publication_year=2016&amp;pmid=27266854&amp;doi=10.1161/CIRCHEARTFAILURE.115.003116&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF9">
<span class="label">9.</span><cite>Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. Solomon SD, McMurray JJ, Anand IS, et al.  N Engl J Med. 2019;381:1609–1620. doi: 10.1056/NEJMoa1908655.</cite> [<a href="https://doi.org/10.1056/NEJMoa1908655" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31475794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Angiotensin-neprilysin%20inhibition%20in%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=381&amp;publication_year=2019&amp;pages=1609-1620&amp;pmid=31475794&amp;doi=10.1056/NEJMoa1908655&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF10">
<span class="label">10.</span><cite>Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Ferreira JP, Cleland JG, Girerd N, et al.  Eur J Heart Fail. 2023;25:108–113. doi: 10.1002/ejhf.2726.</cite> [<a href="https://doi.org/10.1002/ejhf.2726" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36303266/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Spironolactone%20effect%20on%20cardiac%20structure%20and%20function%20of%20patients%20with%20heart%20failure%20and%20preserved%20ejection%20fraction:%20a%20pooled%20analysis%20of%20three%20randomized%20trials&amp;volume=25&amp;publication_year=2023&amp;pages=108-113&amp;pmid=36303266&amp;doi=10.1002/ejhf.2726&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF11">
<span class="label">11.</span><cite>Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. Solomon SD, McMurray JJ, Claggett B, et al.  N Engl J Med. 2022;387:1089–1098. doi: 10.1056/NEJMoa2206286.</cite> [<a href="https://doi.org/10.1056/NEJMoa2206286" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36027570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Dapagliflozin%20in%20heart%20failure%20with%20mildly%20reduced%20or%20preserved%20ejection%20fraction&amp;volume=387&amp;publication_year=2022&amp;pages=1089-1098&amp;pmid=36027570&amp;doi=10.1056/NEJMoa2206286&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF12">
<span class="label">12.</span><cite>Empagliflozin in heart failure with a preserved ejection fraction. Anker SD, Butler J, Filippatos G, et al.  N Engl J Med. 2021;385:1451–1461. doi: 10.1056/NEJMoa2107038.</cite> [<a href="https://doi.org/10.1056/NEJMoa2107038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34449189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Empagliflozin%20in%20heart%20failure%20with%20a%20preserved%20ejection%20fraction&amp;volume=385&amp;publication_year=2021&amp;pages=1451-1461&amp;pmid=34449189&amp;doi=10.1056/NEJMoa2107038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF13">
<span class="label">13.</span><cite>Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Aroda VR, Ahmann A, Cariou B, et al.  Diabetes Metab. 2019;45:409–418. doi: 10.1016/j.diabet.2018.12.001.</cite> [<a href="https://doi.org/10.1016/j.diabet.2018.12.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30615985/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab&amp;title=Comparative%20efficacy,%20safety,%20and%20cardiovascular%20outcomes%20with%20once-weekly%20subcutaneous%20semaglutide%20in%20the%20treatment%20of%20type%202%20diabetes:%20insights%20from%20the%20SUSTAIN%201-7%20trials&amp;volume=45&amp;publication_year=2019&amp;pages=409-418&amp;pmid=30615985&amp;doi=10.1016/j.diabet.2018.12.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF14">
<span class="label">14.</span><cite>Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Kushner RF, Calanna S, Davies M, et al.  Obesity (Silver Spring) 2020;28:1050–1061. doi: 10.1002/oby.22794.</cite> [<a href="https://doi.org/10.1002/oby.22794" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7318657/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32441473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Obesity%20(Silver%20Spring)&amp;title=Semaglutide%202.4%20mg%20for%20the%20treatment%20of%20obesity:%20key%20elements%20of%20the%20STEP%20trials%201%20to%205&amp;volume=28&amp;publication_year=2020&amp;pages=1050-1061&amp;pmid=32441473&amp;doi=10.1002/oby.22794&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF15">
<span class="label">15.</span><cite>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Marso SP, Bain SC, Consoli A, et al.  N Engl J Med. 2016;375:1834–1844. doi: 10.1056/NEJMoa1607141.</cite> [<a href="https://doi.org/10.1056/NEJMoa1607141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&amp;volume=375&amp;publication_year=2016&amp;pages=1834-1844&amp;pmid=27633186&amp;doi=10.1056/NEJMoa1607141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF16">
<span class="label">16.</span><cite>Semaglutide in patients with heart failure with preserved ejection fraction and obesity. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.  N Engl J Med. 2023;389:1069–1084. doi: 10.1056/NEJMoa2306963.</cite> [<a href="https://doi.org/10.1056/NEJMoa2306963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37622681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Semaglutide%20in%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction%20and%20obesity&amp;volume=389&amp;publication_year=2023&amp;pages=1069-1084&amp;pmid=37622681&amp;doi=10.1056/NEJMoa2306963&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF17">
<span class="label">17.</span><cite>Heart disease and Stroke Statistics-2022 update: a report from the American Heart Association. Tsao CW, Aday AW, Almarzooq ZI, et al.  Circulation. 2022;145:0–639. doi: 10.1161/CIR.0000000000001052.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000001052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35078371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Heart%20disease%20and%20Stroke%20Statistics-2022%20update:%20a%20report%20from%20the%20American%20Heart%20Association&amp;volume=145&amp;publication_year=2022&amp;pages=0-639&amp;pmid=35078371&amp;doi=10.1161/CIR.0000000000001052&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF18">
<span class="label">18.</span><cite>Projected U.S. state-level prevalence of adult obesity and severe obesity. Ward ZJ, Bleich SN, Cradock AL, et al.  N Engl J Med. 2019;381:2440–2450. doi: 10.1056/NEJMsa1909301.</cite> [<a href="https://doi.org/10.1056/NEJMsa1909301" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31851800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Projected%20U.S.%20state-level%20prevalence%20of%20adult%20obesity%20and%20severe%20obesity&amp;volume=381&amp;publication_year=2019&amp;pages=2440-2450&amp;pmid=31851800&amp;doi=10.1056/NEJMsa1909301&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF19">
<span class="label">19.</span><cite>Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥60 years with acute decompensated heart failure with preserved versus reduced ejection fraction. Warraich HJ, Kitzman DW, Whellan DJ, et al.  Circ Heart Fail. 2018;11:0. doi: 10.1161/CIRCHEARTFAILURE.118.005254.</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.118.005254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6380360/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30571197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=Physical%20function,%20frailty,%20cognition,%20depression,%20and%20quality%20of%20life%20in%20hospitalized%20adults%20%E2%89%A560%20years%20with%20acute%20decompensated%20heart%20failure%20with%20preserved%20versus%20reduced%20ejection%20fraction&amp;volume=11&amp;publication_year=2018&amp;pages=0&amp;pmid=30571197&amp;doi=10.1161/CIRCHEARTFAILURE.118.005254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF20">
<span class="label">20.</span><cite>Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. Shah KS, Xu H, Matsouaka RA, et al.  J Am Coll Cardiol. 2017;70:2476–2486. doi: 10.1016/j.jacc.2017.08.074.</cite> [<a href="https://doi.org/10.1016/j.jacc.2017.08.074" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29141781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Heart%20failure%20with%20preserved,%20borderline,%20and%20reduced%20ejection%20fraction:%205-year%20outcomes&amp;volume=70&amp;publication_year=2017&amp;pages=2476-2486&amp;pmid=29141781&amp;doi=10.1016/j.jacc.2017.08.074&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF21">
<span class="label">21.</span><cite>The pathophysiology of heart failure with preserved ejection fraction. Borlaug BA. Nat Rev Cardiol. 2014;11:507–515. doi: 10.1038/nrcardio.2014.83.</cite> [<a href="https://doi.org/10.1038/nrcardio.2014.83" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24958077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cardiol&amp;title=The%20pathophysiology%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=11&amp;publication_year=2014&amp;pages=507-515&amp;pmid=24958077&amp;doi=10.1038/nrcardio.2014.83&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF22">
<span class="label">22.</span><cite>Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Circulation. 2017;136:6–19. doi: 10.1161/CIRCULATIONAHA.116.026807.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.116.026807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5501170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28381470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Evidence%20supporting%20the%20existence%20of%20a%20distinct%20obese%20phenotype%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=136&amp;publication_year=2017&amp;pages=6-19&amp;pmid=28381470&amp;doi=10.1161/CIRCULATIONAHA.116.026807&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF23">
<span class="label">23.</span><cite>Heart failure with preserved ejection fraction. Redfield MM. N Engl J Med. 2016;375:1868–1877. doi: 10.1056/NEJMcp1511175.</cite> [<a href="https://doi.org/10.1056/NEJMcp1511175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27959663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=375&amp;publication_year=2016&amp;pages=1868-1877&amp;pmid=27959663&amp;doi=10.1056/NEJMcp1511175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF24">
<span class="label">24.</span><cite>Phenomapping for novel classification of heart failure with preserved ejection fraction. Shah SJ, Katz DH, Selvaraj S, et al.  Circulation. 2015;131:269–279. doi: 10.1161/CIRCULATIONAHA.114.010637.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.114.010637" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4302027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25398313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Phenomapping%20for%20novel%20classification%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;volume=131&amp;publication_year=2015&amp;pages=269-279&amp;pmid=25398313&amp;doi=10.1161/CIRCULATIONAHA.114.010637&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF25">
<span class="label">25.</span><cite>Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction? Lund LH, Eldhagen P. Eur J Heart Fail. 2022;24:2387–2389. doi: 10.1002/ejhf.2678.</cite> [<a href="https://doi.org/10.1002/ejhf.2678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36066359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Diagnosing%20heart%20failure%20with%20preserved%20ejection%20fraction%20in%20cardiac%20amyloidosis%20or%20diagnosing%20cardiac%20amyloidosis%20in%20heart%20failure%20with%20preserved%20ejection%20fraction?&amp;volume=24&amp;publication_year=2022&amp;pages=2387-2389&amp;pmid=36066359&amp;doi=10.1002/ejhf.2678&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF26">
<span class="label">26.</span><cite>Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. van Woerden G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, Rienstra M, Gorter TM. Eur J Heart Fail. 2022;24:2238–2250. doi: 10.1002/ejhf.2741.</cite> [<a href="https://doi.org/10.1002/ejhf.2741" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10100217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36394512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Connecting%20epicardial%20adipose%20tissue%20and%20heart%20failure%20with%20preserved%20ejection%20fraction:%20mechanisms,%20management%20and%20modern%20perspectives&amp;volume=24&amp;publication_year=2022&amp;pages=2238-2250&amp;pmid=36394512&amp;doi=10.1002/ejhf.2741&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF27">
<span class="label">27.</span><cite>Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Husain M, Birkenfeld AL, Donsmark M, et al.  N Engl J Med. 2019;381:841–851. doi: 10.1056/NEJMoa1901118.</cite> [<a href="https://doi.org/10.1056/NEJMoa1901118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31185157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Oral%20semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&amp;volume=381&amp;publication_year=2019&amp;pages=841-851&amp;pmid=31185157&amp;doi=10.1056/NEJMoa1901118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF28">
<span class="label">28.</span><cite>Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. Packer M. J Am Coll Cardiol. 2018;71:2360–2372. doi: 10.1016/j.jacc.2018.03.509.</cite> [<a href="https://doi.org/10.1016/j.jacc.2018.03.509" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29773163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Epicardial%20adipose%20tissue%20may%20mediate%20deleterious%20effects%20of%20obesity%20and%20inflammation%20on%20the%20myocardium&amp;volume=71&amp;publication_year=2018&amp;pages=2360-2372&amp;pmid=29773163&amp;doi=10.1016/j.jacc.2018.03.509&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF29">
<span class="label">29.</span><cite>Semaglutide in patients with obesity-related heart failure and type 2 diabetes. Kosiborod MN, Petrie MC, Borlaug BA, et al.  N Engl J Med. 2024;390:1394–1407. doi: 10.1056/NEJMoa2313917.</cite> [<a href="https://doi.org/10.1056/NEJMoa2313917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38587233/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Semaglutide%20in%20patients%20with%20obesity-related%20heart%20failure%20and%20type%202%20diabetes&amp;volume=390&amp;publication_year=2024&amp;pages=1394-1407&amp;pmid=38587233&amp;doi=10.1056/NEJMoa2313917&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF30">
<span class="label">30.</span><cite>GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. Patel R, Wadid M, Makwana B, et al.  JACC Heart Fail. 2024;12:1814–1826. doi: 10.1016/j.jchf.2024.07.006.</cite> [<a href="https://doi.org/10.1016/j.jchf.2024.07.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39207323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=GLP-1%20receptor%20agonists%20among%20patients%20with%20overweight%20or%20obesity,%20diabetes,%20and%20HFpEF%20on%20SGLT2%20inhibitors&amp;volume=12&amp;publication_year=2024&amp;pages=1814-1826&amp;pmid=39207323&amp;doi=10.1016/j.jchf.2024.07.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF31">
<span class="label">31.</span><cite>Tirzepatide for heart failure with preserved ejection fraction and obesity. Packer M, Zile MR, Kramer CM, et al.  N Engl J Med. 2025;392:427–437. doi: 10.1056/NEJMoa2410027.</cite> [<a href="https://doi.org/10.1056/NEJMoa2410027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39555826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tirzepatide%20for%20heart%20failure%20with%20preserved%20ejection%20fraction%20and%20obesity&amp;volume=392&amp;publication_year=2025&amp;pages=427-437&amp;pmid=39555826&amp;doi=10.1056/NEJMoa2410027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF32">
<span class="label">32.</span><cite>Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Adamson C, Kondo T, Jhund PS, et al.  Eur Heart J. 2022;43:4406–4417. doi: 10.1093/eurheartj/ehac481.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehac481" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9622300/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36029309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Dapagliflozin%20for%20heart%20failure%20according%20to%20body%20mass%20index:%20the%20DELIVER%20trial&amp;volume=43&amp;publication_year=2022&amp;pages=4406-4417&amp;pmid=36029309&amp;doi=10.1093/eurheartj/ehac481&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF33">
<span class="label">33.</span><cite>Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. Kitzman DW, Brubaker P, Morgan T, et al.  JAMA. 2016;315:36–46. doi: 10.1001/jama.2015.17346.</cite> [<a href="https://doi.org/10.1001/jama.2015.17346" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4787295/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26746456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect%20of%20caloric%20restriction%20or%20aerobic%20exercise%20training%20on%20peak%20oxygen%20consumption%20and%20quality%20of%20life%20in%20obese%20older%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction:%20a%20randomized%20clinical%20trial&amp;volume=315&amp;publication_year=2016&amp;pages=36-46&amp;pmid=26746456&amp;doi=10.1001/jama.2015.17346&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF34">
<span class="label">34.</span><cite>The discovery and development of liraglutide and semaglutide. Knudsen LB, Lau J. Front Endocrinol (Lausanne) 2019;10:155. doi: 10.3389/fendo.2019.00155.</cite> [<a href="https://doi.org/10.3389/fendo.2019.00155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6474072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31031702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Endocrinol%20(Lausanne)&amp;title=The%20discovery%20and%20development%20of%20liraglutide%20and%20semaglutide&amp;volume=10&amp;publication_year=2019&amp;pages=155&amp;pmid=31031702&amp;doi=10.3389/fendo.2019.00155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF35">
<span class="label">35.</span><cite>Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Jensen L, Helleberg H, Roffel A, et al.  Eur J Pharm Sci. 2017;104:31–41. doi: 10.1016/j.ejps.2017.03.020.</cite> [<a href="https://doi.org/10.1016/j.ejps.2017.03.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28323117/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Pharm%20Sci&amp;title=Absorption,%20metabolism%20and%20excretion%20of%20the%20GLP-1%20analogue%20semaglutide%20in%20humans%20and%20nonclinical%20species&amp;volume=104&amp;publication_year=2017&amp;pages=31-41&amp;pmid=28323117&amp;doi=10.1016/j.ejps.2017.03.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF36">
<span class="label">36.</span><cite>Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Diabetologia. 1998;41:271–278. doi: 10.1007/s001250050903.</cite> [<a href="https://doi.org/10.1007/s001250050903" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9541166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Dipeptidyl%20peptidase%20IV%20resistant%20analogues%20of%20glucagon-like%20peptide-1%20which%20have%20extended%20metabolic%20stability%20and%20improved%20biological%20activity&amp;volume=41&amp;publication_year=1998&amp;pages=271-278&amp;pmid=9541166&amp;doi=10.1007/s001250050903&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF37">
<span class="label">37.</span><cite>The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Nauck MA. Lancet. 2006;368:1696–1705. doi: 10.1016/S0140-6736(06)69705-5.</cite> [<a href="https://doi.org/10.1016/S0140-6736(06)69705-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17098089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=The%20incretin%20system:%20glucagon-like%20peptide-1%20receptor%20agonists%20and%20dipeptidyl%20peptidase-4%20inhibitors%20in%20type%202%20diabetes&amp;volume=368&amp;publication_year=2006&amp;pages=1696-1705&amp;pmid=17098089&amp;doi=10.1016/S0140-6736(06)69705-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF38">
<span class="label">38.</span><cite>Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Diabetes Metab Res Rev. 2014;30:354–371. doi: 10.1002/dmrr.2501.</cite> [<a href="https://doi.org/10.1002/dmrr.2501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24989141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab%20Res%20Rev&amp;title=Incretins:%20their%20physiology%20and%20application%20in%20the%20treatment%20of%20diabetes%20mellitus&amp;volume=30&amp;publication_year=2014&amp;pages=354-371&amp;pmid=24989141&amp;doi=10.1002/dmrr.2501&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF39">
<span class="label">39.</span><cite>Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. J Endocrinol. 2014;221:0–16. doi: 10.1530/JOE-13-0414.</cite> [<a href="https://doi.org/10.1530/JOE-13-0414" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24323912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Endocrinol&amp;title=Effects%20of%20glucagon-like%20peptide%201%20on%20appetite%20and%20body%20weight:%20focus%20on%20the%20CNS&amp;volume=221&amp;publication_year=2014&amp;pages=0-16&amp;pmid=24323912&amp;doi=10.1530/JOE-13-0414&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF40">
<span class="label">40.</span><cite>Once-weekly semaglutide in adults with overweight or obesity. Wilding JP, Batterham RL, Calanna S, et al.  N Engl J Med. 2021;384:989–1002. doi: 10.1056/NEJMoa2032183.</cite> [<a href="https://doi.org/10.1056/NEJMoa2032183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33567185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity&amp;volume=384&amp;publication_year=2021&amp;pages=989-1002&amp;pmid=33567185&amp;doi=10.1056/NEJMoa2032183&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF41">
<span class="label">41.</span><cite>Cost-effectiveness of semaglutide in patients with obesity and cardiovascular disease. Rennert-May E, Manns B, Clement F, et al.  Can J Cardiol. 2025;41:128–136. doi: 10.1016/j.cjca.2024.09.025.</cite> [<a href="https://doi.org/10.1016/j.cjca.2024.09.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39772331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Cardiol&amp;title=Cost-effectiveness%20of%20semaglutide%20in%20patients%20with%20obesity%20and%20cardiovascular%20disease&amp;volume=41&amp;publication_year=2025&amp;pages=128-136&amp;pmid=39772331&amp;doi=10.1016/j.cjca.2024.09.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF42">
<span class="label">42.</span><cite>Adverse effects of GLP-1 receptor agonists. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Rev Diabet Stud. 2014;11:202–230. doi: 10.1900/RDS.2014.11.202.</cite> [<a href="https://doi.org/10.1900/RDS.2014.11.202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5397288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26177483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Diabet%20Stud&amp;title=Adverse%20effects%20of%20GLP-1%20receptor%20agonists&amp;volume=11&amp;publication_year=2014&amp;pages=202-230&amp;pmid=26177483&amp;doi=10.1900/RDS.2014.11.202&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF43">
<span class="label">43.</span><cite>Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Cardiovasc Res. 2023;118:3434–3450. doi: 10.1093/cvr/cvac120.</cite> [<a href="https://doi.org/10.1093/cvr/cvac120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10202444/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35880317/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Res&amp;title=Obesity%20and%20heart%20failure%20with%20preserved%20ejection%20fraction:%20new%20insights%20and%20pathophysiological%20targets&amp;volume=118&amp;publication_year=2023&amp;pages=3434-3450&amp;pmid=35880317&amp;doi=10.1093/cvr/cvac120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cureus are provided here courtesy of <strong>Cureus Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.7759/cureus.87605"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/cureus-0017-00000087605.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.4 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12333672/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12333672/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333672%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333672/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12333672/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12333672/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40786355/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12333672/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40786355/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12333672/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12333672/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="YpfocGBEiPd3B2hTLH0PaPMV5so2w6XV1d7zjzRSqnCRrfT2NPUvuD6EvbWkhbYi">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
